Iodine promotes the development of papillary thyroid carcinoma via the MAPK signaling pathway through SNAI1

Mechanism Study on the Association between Iodine and Thyroid Papillary Carcinoma Risk

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500112480

Enrollment

Unknown

Registered

2025-11-14

Start date

2025-12-01

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary thyroid carcinoma (PTC)??

Interventions

Papillary thyroid carcinoma group:None

Control group (nodular goiter group):None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Postoperative pathology confirmed as papillary thyroid carcinoma or nodular goiter. 2. Normal thyroid function. 3. No significant dysfunction of the heart, liver, kidneys, or lungs. 4. Signed informed consent form has been obtained.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of neck radiotherapy prior to enrollment. 2. Patients who underwent radionuclide imaging within 8 weeks before surgery. 3. Patients who received iodine-containing contrast agents within 8 weeks before surgery. 4. Patients who took thyroid hormones within 4 weeks before surgery. 5. Patients with severe hepatic or renal dysfunction.

Design outcomes

Primary

Measure	Time frame
Urinary Iodine Concentration;Blood Iodine Concentration;SNAI1 Gene Expression Level in Tissues;	—

Countries

China

Contacts

Public ContactShan Zhou

?Ningbo No. 2 Hospital?

1171931383@qq.com+86 136 8582 8816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026